Using Metoclopramide to Improve Ovarian Response in IVF Patients
Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients: a Randomised, Double-blind, Placebo-controlled Trial
This study is testing if the medication metoclopramide can help women who have trouble responding to IVF treatments produce more eggs.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 54 Years |
| Sex | Female |
| Sponsor | Barzilai Medical Center Academic / other |
| Locations | 1 site (Ashkelon, Ashkelon District) |
| Trial ID | NCT03560583 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the efficacy of metoclopramide in patients undergoing in vitro fertilization (IVF) who are classified as poor responders according to the Bologna criteria. The study aims to determine whether metoclopramide, an antiemetic that blocks dopamine receptors, can enhance ovarian sensitivity to gonadotropins during controlled ovarian stimulation. Participants will receive either metoclopramide or a placebo to assess its impact on oocyte retrieval rates. The trial addresses a significant challenge in reproductive medicine, as no effective protocol has been established for this subgroup of IVF patients.
Who should consider this trial
Good fit: Ideal candidates for this study are women classified as poor responders in IVF according to the Bologna criteria.
Not a fit: Patients with allergies to metoclopramide, prolactinemia, or those treated with dopamine agonists may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve ovarian response and increase the chances of successful IVF outcomes for patients with poor ovarian response.
How similar studies have performed: While this approach is novel for poor responders in IVF, similar studies using metoclopramide in other contexts have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Poor response according to "Bologna criteria" Exclusion Criteria: * Allergy to metoclopramide * Prolactinemia * Women treated with dopamine agonists
Where this trial is running
Ashkelon, Ashkelon District
- Barzilai University Medical Center — Ashkelon, Ashkelon District, Israel (Recruiting)
Study contacts
- Principal investigator: Leon Grin, MD — Barzilai Medical Center
- Study coordinator: Leon Grin, MD
- Email: leonti.grin@gmail.com
- Phone: 972-50-5999379
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.